GPNMB and Parkinson disease: The largest effects were observed for GPNMB, followed by MMP9 and TRIM22, where a one-standard-deviation increase in genetically proxied expression corresponded to approximately 33%, 29.7%, and 20.5% higher odds of PD, respectively.